


PRODUCT: JZL195**ALTERNATE NAME:** 4-[(3-Phenoxyphenyl)methyl]-1-piperazinecarboxylic acid 4-nitrophenyl ester**CATALOG #:** B1064-5, 25**AMOUNT:** 5 mg, 25 mg**STRUCTURE:****MOLECULAR FORMULA:** C₂₄H₂₃N₃O₅**MOLECULAR WEIGHT:** 433.46**CAS NUMBER:** 1210004-12-8**APPEARANCE:** White to off-white solid**SOLUBILITY:** DMSO (>20 mg/ml)**PURITY:** ≥98% by HPLC**STORAGE:** Store at -20 °C. Protect from moisture**DESCRIPTION:** JZL195 is a potent dual inhibitor of Monoacylglycerol lipase (MAGL) (IC₅₀ = 2 nM) and fatty acid amide hydrolase (FAAH) (IC₅₀ = 4 nM), enzymes that degrade the endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (AEA), the endogenous ligands for the cannabinoid G-protein coupled receptors CB1 and CB2. It poorly inhibits neuropathy target esterase and ABHD6 and does not inhibit other brain serine hydrolases. JZL 195 displays time-dependent inhibition of FAAH and MAGL *in vivo*, consistent with a covalent mechanism of activation.**REFERENCE:** Long, J.Z., *et al.* (2009). *Proc. Natl. Acad. Sci. USA* **106**, 20270-20275.**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.**RELATED PRODUCTS:**FAAH Inhibitor, PF-622 (**1928**)JNJ-1661010 (**2413**)EZSolution™ MFAP (**2811**)**USAGE:** **FOR RESEARCH USE ONLY! Not to be used in humans**